What would you like to know?
Handok Pharmaceuticals is dedicated
to improving human health and the quality of life.
to improving human health and the quality of life.
A Transparent Governance Structure
can Enhance the Trust and Value of the Company
can Enhance the Trust and Value of the Company
Shareholder Structure
| Category | Name | Type of Shares | Number of Shares Owned | Ownership Percentage | Remarks |
|---|---|---|---|---|---|
| Majority Shareholder | Kim Young-jin | Common Shares | 5,971,143 | 43.38% | Related Party: Kim Young-jin and 10 others |
| Employ Stock Ownership | Employee Stock Ownership Association | Common Shares | 8,732 | 0.06% | – |
| Registered Executive | Baek Jin-ki | Common Shares | 1,736 | 0.01% | – |
* As of December 31, 2023
Dividend Status
Our company considers an appropriate dividend rate while taking into account investments for continuous growth, enhancement of shareholder value, and the business environment within the range of distributable profits. Over the past 5 years (2018-2022), we have maintained a separate standard dividend payout ratio of 30% or more (total dividend amount/net profit) and plan to continue this trend for the next 3 years to improve predictability of dividends. We will continue our efforts to meet shareholders’ expectations for value enhancement and returns.
| Category | 2023 | 2022 | 2021 | 2020 | 2019 | ||
|---|---|---|---|---|---|---|---|
| Cash | Dividend Amount | 4,129 | 5,505 | 4,817 | 4,129 | 3,785 | |
| Per Share Dividend (KRW) | Majority Shareholder | 300 | 400 | 350 | 300 | 275 | |
| Small and Other Shareholders | 300 | 400 | 350 | 300 | 275 | ||
| Dividend Yield (%) | 2.2 | 2.4 | 1.5 | 0.9 | 1.2 | ||
| (Separate) Dividend Payout Ratio (%) | – | 30.9 | 42.5 | 47.0 | 33.5 | ||
| (Consolidated) Dividend Payout Ratio (%) | – | 51.5 | 146.2 | 15.3 | 10.8 | ||
| Stock | Total Dividend Shares | – | – | – | – | – | |
| Per Share Dividend Shares | – | – | – | – | – | ||
Board composition
Board Composition Status
| Category | Position (Full-Time/Part-Time) | Name | Appointment Date | Term | Position | Remarks |
|---|---|---|---|---|---|---|
| Inside Director | Full-Time | Kim Young-jin | 2022.03.24 | 3 years | Chairman | Current CEO and Chairman, Board Chairman |
| Full-Time | Baek Jin-ki | 2023.03.24 | 3 years | Representative Director | Current CEO | |
| Full-Time | Kim Mi-yeon | 2024.03.22 | 3 years | President | Current COO | |
| Full-Time | Kim Young | 2023.03.24 | 3 years | Executive Director | – | |
| Full-Time | Kim Daniel Dong- han | 2022.03.24 | 3 years | Executive Director | – | |
| Outside Director | Part-Time | Han Chan-hee | 2022.03.24 | 3 years | Director | Current Adjunct Professor at Yonsei University Graduate School of Economics |
| Part-Time | Kang Chang-yuil | 2023.03.24 | 3 years | Director | Current CEO of Cellid Co., Ltd. | |
| Part-Time | Chung Chin-youb | 2024.03.22 | 3 years | Director | Current Director at Bumin Hospital |
Audit Committee
Audit Committee Operation Status
| Category | Name | Insurance Coverage |
|---|---|---|
| Outside Director | Han Chan-hee | Partial |
| Kang Chang-yuil | Partial | |
| Chung Chin-youb | Partial |
External Auditor
| Corporate Name | Date of Appointment | Term | Recent Audit Opinion |
|---|---|---|---|
| KPMG Samjong Accounting Corp | 2022.12.14 | 2023.01.01 ~ 2025.12.31 | Unqualified |
- 132, Teheran-ro, Gangnam-gu, Seoul, 06235, Korea
- 82-2-527-5114
Copyright © HANDOK. All Rights Reserved
